Releases
SRNE
0.0030
-16.67%
-0.0006
  • All
  • Financials
  • Insiders
More
Webull provides the latest Sorrento Therapeutics Inc (SRNE) stock and general news. This information may help you make smarter investment decisions.
About SRNE
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. It is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.